◎ Sugi Atlas

Atlas / Disease / Autonomic nervous system disorder

Autonomic nervous system disorder

disease
On this page

Also known as ANS (autonomic nervous system) diseasesANS diseaseANS diseasesautonomic central nervous system diseasesautonomic diseaseautonomic diseasesautonomic dysfunction, segmentalautonomic dysfunctions, segmentalautonomic nervous diseaseautonomic nervous system diseaseautonomic nervous system disease or disorderautonomic nervous system disordersautonomic peripheral nervous system diseasescentral autonomic nervous system diseasesdisease of autonomic nervous systemdisease or disorder of autonomic nervous systemdisorder of autonomic nervous systemdisorder of peripheral autonomic nervous systemdisorder of the autonomic nervous systemdisorders of the autonomic nervous system

Summary

Autonomic nervous system disorder (MONDO:0001292) is a disease (an umbrella term covering 13 Mondo subtypes) with 3 GWAS associations across 8 studies and 79 clinical trials. Top therapeutic interventions include carbidopa anhydrous, droxidopa, and edrophonium. A subtype of central nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 13 Mondo subtypes
  • GWAS associations: 3
  • Clinical trials: 79

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameautonomic nervous system disorder
Mondo IDMONDO:0001292
EFOEFO:0009532
MeSHD001342
DOIDDOID:11465
ICD-111397803237
SNOMED CT128123007, 15241006
UMLSC1145628
MedGen218837
Anatomy (UBERON)UBERON:0002410
Is cancer (heuristic)no

Also known as: ANS (autonomic nervous system) diseases · ANS disease · ANS diseases · autonomic central nervous system diseases · autonomic disease · autonomic diseases · autonomic dysfunction, segmental · autonomic dysfunctions, segmental · autonomic nervous disease · autonomic nervous system disease · autonomic nervous system disease or disorder · autonomic nervous system disorders · autonomic peripheral nervous system diseases · central autonomic nervous system diseases · disease of autonomic nervous system · disease or disorder of autonomic nervous system · disorder of autonomic nervous system · disorder of peripheral autonomic nervous system · disorder of the autonomic nervous system · disorders of the autonomic nervous system (+6 more)

Data availability: 3 GWAS associations (8 studies).

Disease family

This is a subtype of central nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autonomic nervous system disorder

Related subtypes (18): autoimmune disorder of central nervous system, optic nerve disorder, spinal cord disorder, high pressure neurological syndrome, central nervous system vasculitis, encephalomyelitis, neurodegenerative disease, brain disorder, central nervous system neoplasm, palsy, trigeminal neuralgia, infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly, sporadic fetal brain disruption sequence, congenital narrowing of cervical spinal canal, central nervous system infectious disorder, cerebrospinal fluid leak, SPAST-related motor disorder, tinnitus

Subtypes (13): idiopathic peripheral autonomic neuropathy, autonomic neuropathy, autonomic nervous system neoplasm, Frey syndrome, harlequin syndrome, chronic hiccup, pure autonomic failure, baroreflex failure, autonomic dysreflexia, dysautonomia, sympathetic nervous system disorder, parasympathetic nervous system disorder, central hypoventilation syndrome, congenital, 1, with or without Hirschsprung disease

Genetics & variants

GWAS landscape

3 GWAS associations across 8 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
chr19:159834854e-13T0.09
rs116733764e-11UCA1-AS1 - CYP4F36PC0.08
rs106441855e-09ELMO1?

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90475834Verma A202414,559421,084Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477521Verma A20242,866114,802Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480015Verma A20242,866114,802Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477520Verma A20241,13557,217Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473367UK Biobank Whole-Genome Sequencing Consortium2025760457,680Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90435914Zhou W2018266395,209Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90726716Kim HI202618243,844Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90651402Liu TY2025139218,635Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic3

MAF distribution

BucketVariants
common (>=0.05)3
low_freq (0.01-0.05)0
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
unknown1
intergenic_variant1
intron_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
chr19:159834850.2894e-13Tier 4: intronic/intergenic
rs116733761915867577C>T0.313intergenic_variantUCA1-AS1 - CYP4F36P4e-11Tier 4: intronic/intergenic
rs10644185737360946C>CAT0.05intron_variantELMO15e-09Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 79.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified64
PHASE24
PHASE13
EARLY_PHASE13
PHASE2/PHASE32
PHASE1/PHASE22
PHASE41

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01524861PHASE4COMPLETEDSympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy
NCT07071350PHASE2/PHASE3RECRUITINGRandomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms
NCT00581477PHASE2/PHASE3TERMINATEDTreatment of Orthostatic Hypotension
NCT06073886PHASE2RECRUITINGPersonalized Brain Stimulation to Treat Chronic Concussive Symptoms
NCT00221689PHASE2TERMINATEDIntrathecal Baclofen Therapy and Paroxysmal Dysautonomia in Severe Brain-Injured Patients
NCT00547911PHASE1/PHASE2TERMINATEDAugmenting Effects of L-DOPS With Carbidopa and Entacapone
NCT01343329PHASE1/PHASE2WITHDRAWNControlling Hyperadrenergic Activity in Neurologic Injury
NCT03426085PHASE2UNKNOWNThe Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
NCT03674541PHASE2COMPLETEDThe Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
NCT00748059PHASE1COMPLETEDThe Pathophysiology of Orthostatic Hypotension
NCT04121338PHASE1COMPLETEDTemporary Celiac Ganglion Block as a Test Before Celiac Ganglion Resection for Dysautonomia-Related Bowel Dysmotility
NCT05638620PHASE1COMPLETEDDual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
NCT02385877EARLY_PHASE1COMPLETEDClinical Translation of 18F-Labeled Hydroxyphenethylguanidines
NCT02591173EARLY_PHASE1TERMINATEDBlood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
NCT02963181EARLY_PHASE1TERMINATEDEffects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension
NCT02725060Not specifiedENROLLING_BY_INVITATIONAutoimmune Basis for Postural Tachycardia Syndrome
NCT04100486Not specifiedENROLLING_BY_INVITATIONNon-Invasive Bioelectronic Analytics
NCT04806620Not specifiedRECRUITINGUnhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
NCT05004857Not specifiedACTIVE_NOT_RECRUITINGThe Effect of Reading Therapy on Newborns
NCT05041387Not specifiedRECRUITINGData Collection of Standard Care of Patients in the EMG Section
NCT05212129Not specifiedRECRUITINGAuricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome
NCT05400174Not specifiedRECRUITINGBlood Pressure Effects on Cognition and Brain Blood Flow in PD
NCT05741112Not specifiedRECRUITINGThe Long COVID-19 Wearable Device Study
NCT06236945Not specifiedRECRUITINGHUTT to Assess Cardiac Autonomic Nervous Function
NCT06554834Not specifiedRECRUITINGEffects of Osteopathic Technique on Autonomic Nervous System Activity
NCT06863207Not specifiedRECRUITINGAutonomic Reactivity and Personalized Neurostimulation
NCT07196397Not specifiedRECRUITINGPOLish Registry of CArdioneuroablation and CArdioneuromodulation
NCT07405515Not specifiedACTIVE_NOT_RECRUITINGPathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19
NCT07409363Not specifiedNOT_YET_RECRUITINGNon-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain
NCT07468383Not specifiedRECRUITINGBasic and Clinical Study of Cardiac Ganglion Catheter Ablation for the Treatment of Significant Bradycardia
NCT07481292Not specifiedENROLLING_BY_INVITATIONNeuro-Emotional Release: Veins and Endocrine System (NERVE) Therapy for Children With Dysautonomia
NCT07560800Not specifiedNOT_YET_RECRUITINGEffect of Beetroot Juice on Cardiovascular and Autonomic Responses to Exercise in Adults With Type 2 Diabetes
NCT07577739Not specifiedNOT_YET_RECRUITINGNoninvasive CA Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage
NCT07615790Not specifiedRECRUITINGStructured Combined Exercise Program in Postmenopausal Women: Effects on Heart Rate Variability and Menopausal Symptoms
NCT00001147Not specifiedCOMPLETEDBlood Sampling for Neurochemical and Genetic Testing
NCT00001329Not specifiedCOMPLETEDStudy of Norepinephrine Levels and Sympathetic Nervous System Activity
NCT00001418Not specifiedCOMPLETEDPET Scan in Patients With Neurocardiologic Disorders
NCT00059033Not specifiedTERMINATEDEvaluation of Primary Chronic Autonomic Failure
NCT00422474Not specifiedUNKNOWNPrognostic Significance of the Baroreflex Sensitivity Changes After Acute Ischemic Stroke
NCT00565526Not specifiedCOMPLETEDEvaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CARBIDOPA ANHYDROUS43
DROXIDOPA42
EDROPHONIUM42
ISOPROTERENOL42
PYRIDOSTIGMINE42
ATROPINE41
BACLOFEN41
ENTACAPONE41
ESMOLOL41
LEVOCARNITINE41
METHYLDOPA41
METOCLOPRAMIDE41
NITROPRUSSIDE41
PHENYLEPHRINE41
YOHIMBINE32
CARNITINE31
LIPOIC ACID, ALPHA31
TYRAMINE31
TALFIRASTIDE21
CHEMBL159385102
CHEMBL377040601
CHEMBL410298201
CHEMBL455743301

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 22

This page pulls from 22 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpdoidefogenccgwasgwas_studyhgncicd11medgenmeshmimmondomondochildmondoparentorphanetsctiduberonumls